Bristol Myers Squibb stock after-hours at EUR 54.10 on October 2, 2026
π BMY stock traded at EUR 54.10 after-hours on October 2, 2026.
π FDA approved CAMZYOS for adults and pediatric patients (β₯30kg) with symptomatic obstructive hypertrophic cardiomyopathy.
πΆ Approval relies on Phase 3 SCOUT-HCM trial results from 44 adolescent patients.
π€ BMY announced a $1 million grant program for nonprofits supporting medically underserved communities.
π Grant nominations are due by November 30, 2026.
Bullish Signals
- Bristol Myers Squibb secured FDA approval for CAMZYOS in adults and pediatric patients weighing at least 30 kilograms for symptomatic obstructive hypertrophic cardiomyopathy.
- The company's Phase 3 SCOUT-HCM trial successfully enrolled 44 adolescent patients to support the regulatory approval of its new drug indication.
Full Analysis
Bristol Myers Squibb (BMY) traded at EUR 54.10 in after-hours trading on October 2, 2026, with a bid of EUR 53.99 and an ask of EUR 54.21 according to Lang & Schwarz.
The company received FDA approval for its drug CAMZYOS for treating symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms. This regulatory milestone was based on data from the Phase 3 SCOUT-HCM trial, which enrolled 44 adolescent patients.
Additionally, Bristol Myers Squibb announced a $1 million grant program for nonprofit organizations supporting medically underserved communities in the United States, with nominations due by November 30, 2026.